Yedidya Saiman, MD, PhD, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University, offered insight to the Philadelphia Inquirer on Rezdiffra, or resmetirom, which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of scarring and inflammation caused by abnormal accumulations of fat in the liver. The condition is known as metabolic dysfunction-associated steatohepatitis (MASH), or fatty liver disease. Dr. Saiman was not involved in the study of Rezdiffra.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH